Encouraging preliminary data from Lytix Biopharma’s ATLAS-IT-05 study presented at ESMO 2023
Oslo, 23 October 2023. Lytix Biopharma – Lytix Biopharma AS (“Lytix”) (Euronext Growth Oslo: LYTIX), a clinical stage immuno-oncology company, announces that Dr Stephane Dalle, the top recruiting investigator of the ATLAS-IT-05 study, will give a poster presentation today at the ESMO 2023 Congress.
ATLAS-IT-05 is a Phase II open label clinical trial with LTX-315 in combination with Keytruda® (pembrolizumab) in stage III-IV melanoma patients refractory to treatment with PD-1 / PD-L1 inhibitors.